[go: up one dir, main page]

SV2018005750A - Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue - Google Patents

Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue

Info

Publication number
SV2018005750A
SV2018005750A SV2018005750A SV2018005750A SV2018005750A SV 2018005750 A SV2018005750 A SV 2018005750A SV 2018005750 A SV2018005750 A SV 2018005750A SV 2018005750 A SV2018005750 A SV 2018005750A SV 2018005750 A SV2018005750 A SV 2018005750A
Authority
SV
El Salvador
Prior art keywords
dengue
compounds
viric
replication
inhibitors
Prior art date
Application number
SV2018005750A
Other languages
English (en)
Inventor
Dorothée Alice Marie-Eve Bardiot
Jean Françoise Bonfanti
Erwin Coesemans
Bart Rudolf Romanie Kesteleyn
Arnaud Didier M Marchand
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of SV2018005750A publication Critical patent/SV2018005750A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • C07F9/5728Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCIÓN TRATA SOBRE COMPUESTOS DE INDOL SUSTITUIDOS, MÉTODOS PARA PREVENIR O TRATAR INFECCIONES VÍRICAS POR DENGUE UTILIZANDO DICHOS COMPUESTOS Y TAMBIÉN SE REFIERE A DICHOS COMPUESTOS PARA SU USO COMO UN MEDICAMENTO, MÁS PREFERENTEMENTE, PARA SU USO COMO UN MEDICAMENTO PARA TRATAR O PREVENIR INFECCIONES VÍRICAS POR DENGUE. LA PRESENTE INVENCIÓN SE REFIERE ADEMÁS A COMPOSICIONES FARMACÉUTICAS O PREPARADOS COMBINADOS DE LOS COMPUESTOS, A LAS COMPOSICIONES O PREPARADOS PARA SU USO COMO UN MEDICAMENTO, MÁS PREFERENTEMENTE PARA LA PREVENCIÓN O EL TRATAMIENTO DE INFECCIONES VÍRICAS POR DENGUE. LA INVENCIÓN TAMBIÉN SE REFIERE A PROCESOS PARA LA PREPARACIÓN DE LOS COMPUESTOS.
SV2018005750A 2016-04-01 2018-09-28 Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue SV2018005750A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16163482 2016-04-01

Publications (1)

Publication Number Publication Date
SV2018005750A true SV2018005750A (es) 2018-11-15

Family

ID=55650310

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005750A SV2018005750A (es) 2016-04-01 2018-09-28 Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue

Country Status (21)

Country Link
US (1) US10730884B2 (es)
EP (1) EP3436004B1 (es)
JP (2) JP7007290B2 (es)
KR (1) KR102359766B1 (es)
CN (1) CN109069482B (es)
AU (1) AU2017240076A1 (es)
BR (1) BR112018068956A2 (es)
CA (1) CA3013408A1 (es)
CL (1) CL2018002784A1 (es)
CO (1) CO2018009996A2 (es)
CR (1) CR20180494A (es)
EA (1) EA201892200A1 (es)
EC (1) ECSP18073264A (es)
ES (1) ES3010298T3 (es)
IL (1) IL261947A (es)
MA (1) MA44502A (es)
MX (1) MX2018011786A (es)
PH (1) PH12018502026A1 (es)
SG (1) SG11201808237UA (es)
SV (1) SV2018005750A (es)
WO (1) WO2017167952A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US10646469B2 (en) 2016-03-31 2020-05-12 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
EA201892216A1 (ru) 2016-03-31 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN109069482B (zh) 2016-04-01 2022-04-05 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
TWI771420B (zh) 2017-05-22 2022-07-21 美商健生醫藥公司 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物(一)
AU2018274100B2 (en) 2017-05-22 2022-06-23 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
CN108586404A (zh) * 2018-06-12 2018-09-28 湖南大学 一种n-芳基萘并呋喃酮亚胺类化合物的合成方法
CN108947948B (zh) * 2018-06-12 2021-07-20 湖南大学 一种n-芳基萘并呋喃酮亚胺类化合物及其合成方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
WO2003050295A2 (en) 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
BRPI0516751A (pt) * 2004-09-30 2008-09-16 Tibotec Pharm Ltd pirimidinas bicìclicas que inibem hcv
EP1844042A1 (en) 2005-01-14 2007-10-17 Genelabs Technologies, Inc. Indole derivatives for treating viral infections
EP1853317A2 (en) 2005-02-09 2007-11-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
CN101903026B (zh) * 2007-09-18 2013-05-08 斯坦福大学 抑制剂在制备用于治疗黄病毒家族病毒感染的药物中的用途
AU2009256390A1 (en) 2008-06-03 2009-12-10 Siga Technologies, Inc. Small molecule inhibitors for the treatment or prevention of dengue virus infection
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US8524764B2 (en) 2010-01-15 2013-09-03 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
AU2014338947B2 (en) 2013-10-23 2018-02-22 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
PE20210470A1 (es) 2014-01-31 2021-03-08 Bristol Myers Squibb Co Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia
SI3201176T1 (sl) 2014-10-01 2019-05-31 Janssen Pharmaceuticals, Inc. Mono-ali di-substituirani derivati indola kot inhibitorji replikacije virusa denga
PL3201177T3 (pl) 2014-10-01 2019-05-31 Janssen Pharmaceuticals Inc Mono- lub di-podstawione indole jako inhibitory replikacji wirusa dengi
NO2721243T3 (es) 2014-10-01 2018-10-20
PH12017501272B1 (en) 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX374683B (es) 2015-11-03 2025-03-04 Zoetis Services Llc Compuestos polimericos sol-gel y sus usos.
AU2017245125B2 (en) 2016-03-31 2020-10-22 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10646469B2 (en) 2016-03-31 2020-05-12 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
EA201892216A1 (ru) 2016-03-31 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
PE20190173A1 (es) 2016-04-01 2019-02-01 Kite Pharma Inc Receptores de antigenos quimericos y celulas t y metodos de uso
UA128326C2 (uk) 2016-04-01 2024-06-12 Амджен Інк. Химерний рецептор до flt3 та спосіб його застосування
AU2017240788B2 (en) 2016-04-01 2020-04-09 Amgen Inc. Chimeric receptors and methods of use thereof
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN109069482B (zh) 2016-04-01 2022-04-05 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物
CA3018986A1 (en) 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
JP7027329B2 (ja) 2016-04-01 2022-03-01 ビーエーエスエフ ソシエタス・ヨーロピア 二環式化合物
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
TWI771420B (zh) 2017-05-22 2022-07-21 美商健生醫藥公司 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物(一)
AU2018274100B2 (en) 2017-05-22 2022-06-23 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Also Published As

Publication number Publication date
MX2018011786A (es) 2019-05-20
CR20180494A (es) 2019-01-29
JP2022009166A (ja) 2022-01-14
AU2017240076A1 (en) 2018-08-09
CA3013408A1 (en) 2017-10-05
EP3436004A1 (en) 2019-02-06
KR20180130502A (ko) 2018-12-07
MA44502A (fr) 2019-02-06
CN109069482A (zh) 2018-12-21
ES3010298T3 (en) 2025-04-02
BR112018068956A2 (pt) 2019-01-22
EA201892200A1 (ru) 2019-03-29
EP3436004B1 (en) 2024-12-11
JP2019511502A (ja) 2019-04-25
ECSP18073264A (es) 2018-10-31
EP3436004C0 (en) 2024-12-11
SG11201808237UA (en) 2018-10-30
CN109069482B (zh) 2022-04-05
US10730884B2 (en) 2020-08-04
PH12018502026A1 (en) 2019-02-11
CO2018009996A2 (es) 2018-09-28
US20190276467A1 (en) 2019-09-12
KR102359766B1 (ko) 2022-02-07
WO2017167952A1 (en) 2017-10-05
JP7007290B2 (ja) 2022-01-24
IL261947A (en) 2018-10-31
CL2018002784A1 (es) 2018-12-14

Similar Documents

Publication Publication Date Title
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2018002729A1 (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue.
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2017000782A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue
CO2018003471A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
CO2018003369A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue